Navigation Links
EntreMed's Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
Date:4/14/2008

his high profile session. ENMD-2076 is an exciting compound with demonstrated single-agent activity against a broad range of tumor types. EntreMed recently commenced a Phase 1, dose-escalation study with ENMD-2076 in advanced cancers and plans to initiate a second Phase 1 study in hematological cancers later in 2008."

To view a copy of Dr. Bray's presentation, visit Scientific Presentations under the Therapeutic Pathways section of the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, whi
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
2. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
3. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
4. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
5. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
6. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
7. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
10. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
11. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... (PRWEB) March 02, 2015 The ... ReachMD announced today the launch of Genetically ... educate healthcare professionals on the application of human genetics ... series features peer-to-peer interviews conducted during the ASHG 2014 ... ,     Translational Genomics and Health Outcomes Research: What's Ready ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 In the ... industry has experienced robust growth. The industry, which ... industrial materials, energy resources and other goods, has grown ... government regulation. As a result, IBISWorld forecasts that industry ... to reach $946.8 million over the five-year period, including ...
(Date:3/2/2015)... , March 2, 2015 Analyzing ... experts have identified a new syndrome, shedding light ... research also provides important information to help caregivers ... eventually treating it. "This syndrome illuminates ... sort of master switch that controls many other ...
(Date:3/2/2015)... and VANCOUVER, British Columbia ... ("InMed") (CSE: IN; OTCQB: IMLFF), a clinical stage ... based therapies, today announced that Craig Schneider ... overview during a live webcast at VirtualInvestorConferences.com. ... LINK:   http://VirtualInvestorConferences.com > click the red ...
Breaking Biology Technology:American Society of Human Genetics (ASHG) and ReachMD Launch Series on Genetics and Genomics 2American Society of Human Genetics (ASHG) and ReachMD Launch Series on Genetics and Genomics 3Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 2Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 3New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 2New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 3New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 4InMed Pharmaceuticals to Present Investor Webcast March 5 2
... Pharsight,Corporation (Nasdaq: PHST ), a leading provider of ... announced today that it will be presenting at B. ... April 2, 2008 at the Palms Las,Vegas. Shawn O,Connor, ... and CFO, will be presenting on April 2nd,at 1:30 ...
... 26, Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ),the global specialty biopharmaceutical company, announces the ... plc,("Shares") in connection with the Shire Long Term Incentive Plan ("LTIP")., In accordance ... ... of Shares ...
... the leading provider of,ion channel testing services for ... conference the company,s expanding,line of ion channel services ... need to identify the most promising compounds,and eliminate ... invest millions in,the drug-development process. The 14th Annual ...
Cached Biology Technology:Pharsight to Present at B. Riley & Co. 9th Annual Las Vegas Investor Conference 2Shire plc: Long Term Incentive Plan 2ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 1104 2ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 1104 3
(Date:1/22/2015)... , Jan. 13, 2015 Technology Showcase, Hall E - ... authentication solutions, today announced it will showcase its EyeLock ID ... by the Department of Energy,s Oak Ridge National Laboratory ... Show . EyeLock,s iris identity authentication technology is being used ...
(Date:1/22/2015)... Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication company ... of the Wocket™ smart wallet at CES 2015 in Las ... one of the "11 Hot Products at CES" in a review published ... Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
(Date:1/22/2015)... , January 22, 2015 , ... year  The European Patent Office to present a video ... British nominations to be featured: Christofer Toumazou and ... former finalists and winners of the Award   Starting ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... 27 January, 2010 - A recent special edition of the ... the impact of Hurricane Katrina and an overview of the ... Hurricane Katrina was the most destructive natural disaster in U.S. ... storm surge affected the greatest area, nearly 93,000 square miles. ...
... warming may impair the ability of ecosystems to ... and carbon sequestrationsays the nation,s largest organization of ... Ecological Society of America (ESA) outlines strategies that ... to mitigate and adapt to climate change. ...
... This release is available in Spanish . ... minority groups receive worse health care in the treatment of ... developed countries. This conclusion emerges from a research conducted at ... bibliographic review worldwide to date on health care of this ...
Cached Biology News:A forensic analysis of Hurricane Katrina's impact: methods and findings 2Managing ecosystems in a changing climate 2Managing ecosystems in a changing climate 3Poorer diabetics receive worse care than other in countries with universal health coverage 2Poorer diabetics receive worse care than other in countries with universal health coverage 3
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
...
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
This antibody detects cdc42 on SDS-PAGE immunoblots....
Biology Products: